Tumor lysis syndrome primary prevention: Difference between revisions
Created page with "__NOTOC__ {{Tumor lysis syndrome}} {{CMG}} ==Overview== ==Prevention== Patients about to receive chemotherapy for a cancer with high cell turnover rate, especially lymphomas a..." |
No edit summary |
||
| Line 5: | Line 5: | ||
==Prevention== | ==Prevention== | ||
Patients about to receive chemotherapy for a cancer with high cell turnover rate, especially lymphomas and leukemias, should receive prophylactic oral or IV [[allopurinol]] (a [[xanthine oxidase]] inhibitor, which inhibits uric acid production) as well as adequate IV hydration to maintain a high urine output (> 2.5 L/day). [[Rasburicase]] (Uricase) is an alternative to allopurinol and is reserved for patients who are high-risk in developing TLS. It is a synthetic [[urate oxidase]] enzyme and acts by degrading uric acid. Alkalinization of the urine with [[acetazolamide]] or [[sodium bicarbonate]] is controversial. Routine alkalinization of urine above pH of 7.0 is not recommended. Alkalinization is also not required if uricase is used. | Patients about to receive chemotherapy for a cancer with high cell turnover rate, especially lymphomas and leukemias, should receive prophylactic oral or IV [[allopurinol]] (a [[xanthine oxidase]] inhibitor, which inhibits uric acid production) as well as adequate IV hydration to maintain a high urine output (> 2.5 L/day). [[Rasburicase]] (Uricase) is an alternative to allopurinol and is reserved for patients who are high-risk in developing TLS. It is a synthetic [[urate oxidase]] enzyme and acts by degrading uric acid. Alkalinization of the urine with [[acetazolamide]] or [[sodium bicarbonate]] is controversial. Routine alkalinization of urine above pH of 7.0 is not recommended. Alkalinization is also not required if uricase is used. | ||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Blood]] | [[Category:Blood]] | ||
[[Category:Hematology]] | [[Category:Hematology]] | ||
Revision as of 14:58, 30 August 2015
|
Tumor lysis syndrome Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Tumor lysis syndrome primary prevention On the Web |
|
American Roentgen Ray Society Images of Tumor lysis syndrome primary prevention |
|
Risk calculators and risk factors for Tumor lysis syndrome primary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Prevention
Patients about to receive chemotherapy for a cancer with high cell turnover rate, especially lymphomas and leukemias, should receive prophylactic oral or IV allopurinol (a xanthine oxidase inhibitor, which inhibits uric acid production) as well as adequate IV hydration to maintain a high urine output (> 2.5 L/day). Rasburicase (Uricase) is an alternative to allopurinol and is reserved for patients who are high-risk in developing TLS. It is a synthetic urate oxidase enzyme and acts by degrading uric acid. Alkalinization of the urine with acetazolamide or sodium bicarbonate is controversial. Routine alkalinization of urine above pH of 7.0 is not recommended. Alkalinization is also not required if uricase is used.